Affinia Therapeutics Granted FDA Fast Track Designation For Aftx-201 As A Treatment For People Living With Bag3-Associated Dilated Cardiomyopathy (Dcm)
March 4 (Reuters) - Affinia Therapeutics Inc AFTX.O:
AFFINIA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR AFTX-201 AS A TREATMENT FOR PEOPLE LIVING WITH BAG3-ASSOCIATED DILATED CARDIOMYOPATHY (DCM)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.